ARCA biopharma
Genetically-targeted therapies for cardiovascular diseases.
Launch date
Employees
Market cap
€50.2m
Enterprise valuation
€20m (Public information from Aug 2024)
Share price
$28.8 ABIO
Westminster Colorado (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| EBITDA | (18.2m) | (7.9m) | (5.6m) | (9.7m) | (19.3m) | (10.6m) | (7.2m) |
| Profit | (18.5m) | (7.9m) | (5.5m) | (9.7m) | (19.3m) | (9.9m) | (5.3m) |
| EV / EBITDA | -0.2x | 0.3x | -0.1x | 1.1x | 1.1x | 0.8x | 1.8x |
| R&D budget | 14.1m | 4.2m | 1.8m | 5.0m | 13.8m | 4.7m | 1.0m |
| Date | Investors | Amount | Round |
|---|---|---|---|
$15.0m | Series A | ||
$18.0m | Series B | ||
| N/A | N/A | IPO | |
| N/A | $4.5m | Post IPO Equity | |
| N/A | $1.3m | Post IPO Equity | |
| N/A | $51.7m | Post IPO Equity | |
* | N/A | Acquisition | |
| Total Funding | €30.0m | ||